Cited by

• Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells.

  Kamisango K, Matsumoto T, Akamatsu K, Morikawa K, Tashiro T, Koizumi K. Kamisango K, et al. Jpn J Cancer Res. 1992 Mar;83(3):304-11. doi: 10.1111/j.1349-7006.1992.tb00105.x. Jpn J Cancer Res. 1992. PMID: 1582895 Free PMC article.
• A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.

  Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan ID, Fullerton W, et al. Rankin EM, et al. Br J Cancer. 1992 Feb;65(2):275-81. doi: 10.1038/bjc.1992.55. Br J Cancer. 1992. PMID: 1739629 Free PMC article. Clinical Trial.
• Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.

  Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F. Di Re F, et al. Cancer Chemother Pharmacol. 1990;25(5):355-60. doi: 10.1007/BF00686237. Cancer Chemother Pharmacol. 1990. PMID: 2306797
• Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

  Scanlon KJ, Newman EM, Lu Y, Priest DG. Scanlon KJ, et al. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5. doi: 10.1073/pnas.83.23.8923. Proc Natl Acad Sci U S A. 1986. PMID: 3466165 Free PMC article.
• Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

  Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR. Sharp SY, et al. Cancer Chemother Pharmacol. 1994;35(2):137-43. doi: 10.1007/BF00686636. Cancer Chemother Pharmacol. 1994. PMID: 7987990